Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) which makes the drug Kalydeco, announced that it had reached an agreement with provincial and territorial governments to enable public drug plans to cover the cost of the drug. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) net profit margin is -36.90% and weekly performance is -10.04%. On last trading day company shares ended up $67.12. Analysts mean target price for the company is $90.45. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) distance from 50-day simple moving average (SMA50) is -1.70%.
22nd Century Group, Inc. (NYSEMKT:XXII) announced that the Company will join the Russell 3000, Russell 2000, Russell Global and Russell Microcap Indexes when Russell Investments (Russell) reconstitutes its U.S. and global equity indexes on June 27, 2014. Russell’s announcement of its annual reconstitution of these Russell indexes, which included 22nd Century Group, was listed on the Russell website on Friday, June 13, 2014, after the U.S. stock market closed. 22nd Century Group Inc. (NYSEMKT:XXII) shares fell -8.20% in last trading session and ended the day on $3.47. XXII gross Margin is 92.20% and its return on assets is -468.20%.22nd Century Group Inc. (NYSEMKT:XXII) quarterly performance is -21.85%.
TG Therapeutics, Inc. (NASDAQ:TGTX) on June 13 announced preliminary clinical results from its ongoing Phase 2 study of TG-1101 (ublituximab), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib (IMBRUVICA(TM)), the oral BTK inhibitor from Pharmacyclics/Janssen. TG Therapeutics, Inc. (NASDAQ:TGTX) shares moved down -6.14% in last trading session and was closed at $9.02, while trading in range of $8.82 – $9.80. TG Therapeutics, Inc. (NASDAQ:TGTX) year to date (YTD) performance is 131.28%.
Corcept Therapeutics Incorporated (NASDAQ:CORT) Director G Leonard Baker, Jr. purchased 103,386 shares of Corcept Therapeutics stock on the open market in a transaction dated Wednesday, June 11th. The shares were purchased at an average cost of $2.32 per share, with a total value of $239,855.52. Following the acquisition, the director now directly owns 578,389 shares in the company, valued at approximately $1,341,862. Corcept Therapeutics Incorporated (NASDAQ:CORT) ended the last trading day at $2.28. Company weekly volatility is calculated as 10.08% and price to cash ratio as 5.28.Corcept Therapeutics Incorporated (NASDAQ:CORT) showed a negative weekly performance of -2.15%.
Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) quiet period is set to end on Tuesday, June 17th. Alder Biopharmaceuticals had issued 8,000,000 shares in its initial public offering on May 8th, Analyst RN reports. The total size of the offering was $80,000,000 based on an initial share price of $10.00. Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) weekly performance is 19.81%. On last trading day company shares ended up $18.57. Analysts mean target price for the company is $25.33. Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) distance from 50-day simple moving average (SMA50) is 51.16%.